COSMOS HEALTH INC.

NASDAQ: COSM (Cosmos Health Inc.)

Last update: 13 May, 4:52PM

0.349

0.00 (0.66%)

Previous Close 0.347
Open 0.350
Volume 254,739
Avg. Volume (3M) 451,846
Market Cap 8,122,252
Price / Sales 0.180
Price / Book 0.520
52 Weeks Range
0.311 (-10%) — 1.58 (352%)
Earnings Date 14 Nov 2024
Profit Margin -28.26%
Operating Margin (TTM) -6.08%
Diluted EPS (TTM) -1.09
Quarterly Revenue Growth (YOY) -6.00%
Total Debt/Equity (MRQ) 49.51%
Current Ratio (MRQ) 1.05
Operating Cash Flow (TTM) -4.49 M
Levered Free Cash Flow (TTM) -1.94 M
Return on Assets (TTM) -14.90%
Return on Equity (TTM) -50.03%

Market Trend

Short Term Medium Term
Industry Medical Distribution (US) Mixed Bearish
Medical Distribution (Global) Mixed Bearish
Stock Cosmos Health Inc. - -

AIStockmoo Score

0.5
Analyst Consensus 0.0
Insider Activity NA
Price Volatility 0.5
Technical Moving Averages 2.5
Technical Oscillators -1.0
Average 0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
COSM 8 M - - 0.520
PDCO 3 B 1.67% 20.38 2.80
EDAP 59 M - - 1.54
HSIC 9 B - 23.22 2.80
ZYXI 76 M - 28.00 3.92
AHG 563 M - - 3.42

Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.

Sector Healthcare
Industry Medical Distribution
Investment Style Small Value
% Held by Insiders 31.08%
% Held by Institutions 9.46%

No data within this time range.

No data within this time range.

Date Type Details
24 Jun 2025 Announcement Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
24 Jun 2025 Announcement Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
15 May 2025 Announcement Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
15 May 2025 Announcement Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
07 May 2025 Announcement Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
07 May 2025 Announcement Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
06 May 2025 Announcement Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
06 May 2025 Announcement Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
30 Apr 2025 Announcement Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
30 Apr 2025 Announcement Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
16 Apr 2025 Announcement Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
16 Apr 2025 Announcement Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria